These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 12479221)

  • 21. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.
    Rajendra R; Gounder MK; Saleem A; Schellens JH; Ross DD; Bates SE; Sinko P; Rubin EH
    Cancer Res; 2003 Jun; 63(12):3228-33. PubMed ID: 12810652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Expression establishment and functional analysis of breast cancer resistance protein with doxycycline induced tet regulating system in mouse fibroblast cell line PA317].
    Yuan JH; He ZM; Yu YH; Chen ZC
    Ai Zheng; 2004 Oct; 23(10):1127-33. PubMed ID: 15473921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional analysis of the human variants of breast cancer resistance protein: I206L, N590Y, and D620N.
    Vethanayagam RR; Wang H; Gupta A; Zhang Y; Lewis F; Unadkat JD; Mao Q
    Drug Metab Dispos; 2005 Jun; 33(6):697-705. PubMed ID: 15743976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
    Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
    Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
    Nagashima S; Soda H; Oka M; Kitazaki T; Shiozawa K; Nakamura Y; Takemura M; Yabuuchi H; Fukuda M; Tsukamoto K; Kohno S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):594-600. PubMed ID: 16520985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
    Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
    J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
    Erlichman C; Boerner SA; Hallgren CG; Spieker R; Wang XY; James CD; Scheffer GL; Maliepaard M; Ross DD; Bible KC; Kaufmann SH
    Cancer Res; 2001 Jan; 61(2):739-48. PubMed ID: 11212277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
    Honjo Y; Hrycyna CA; Yan QW; Medina-Pérez WY; Robey RW; van de Laar A; Litman T; Dean M; Bates SE
    Cancer Res; 2001 Sep; 61(18):6635-9. PubMed ID: 11559526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.
    Imai Y; Tsukahara S; Ishikawa E; Tsuruo T; Sugimoto Y
    Jpn J Cancer Res; 2002 Mar; 93(3):231-5. PubMed ID: 11927002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
    Bram EE; Ifergan I; Grimberg M; Lemke K; Skladanowski A; Assaraf YG
    Biochem Pharmacol; 2007 Jun; 74(1):41-53. PubMed ID: 17481587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.
    Kowalski P; Stein U; Scheffer GL; Lage H
    Cancer Gene Ther; 2002 Jul; 9(7):579-86. PubMed ID: 12082458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization.
    Kage K; Tsukahara S; Sugiyama T; Asada S; Ishikawa E; Tsuruo T; Sugimoto Y
    Int J Cancer; 2002 Feb; 97(5):626-30. PubMed ID: 11807788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
    Mishra MN; Vangara KK; Palakurthi S
    Anticancer Res; 2014 Nov; 34(11):6345-51. PubMed ID: 25368234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.
    Ee PL; He X; Ross DD; Beck WT
    Mol Cancer Ther; 2004 Dec; 3(12):1577-83. PubMed ID: 15634651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.
    Komatani H; Kotani H; Hara Y; Nakagawa R; Matsumoto M; Arakawa H; Nishimura S
    Cancer Res; 2001 Apr; 61(7):2827-32. PubMed ID: 11306452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
    Ishii M; Iwahana M; Mitsui I; Minami M; Imagawa S; Tohgo A; Ejima A
    Anticancer Drugs; 2000 Jun; 11(5):353-62. PubMed ID: 10912951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.
    Ross DD; Yang W; Abruzzo LV; Dalton WS; Schneider E; Lage H; Dietel M; Greenberger L; Cole SP; Doyle LA
    J Natl Cancer Inst; 1999 Mar; 91(5):429-33. PubMed ID: 10070941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2.
    Tamura A; Wakabayashi K; Onishi Y; Takeda M; Ikegami Y; Sawada S; Tsuji M; Matsuda Y; Ishikawa T
    Cancer Sci; 2007 Feb; 98(2):231-9. PubMed ID: 17297656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.
    Su Y; Lee SH; Sinko PJ
    Eur J Pharm Sci; 2006 Oct; 29(2):102-10. PubMed ID: 16844360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells.
    Yang CH; Schneider E; Kuo ML; Volk EL; Rocchi E; Chen YC
    Biochem Pharmacol; 2000 Sep; 60(6):831-7. PubMed ID: 10930538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.